| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2691 | 2019 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1762 | 2019 |
| Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial NA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft, MJ Ahn, ... JAMA oncology 6 (5), 661-674, 2020 | 574 | 2020 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 512 | 2021 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 489 | 2019 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 442 | 2020 |
| Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC NA Rizvi, BC Cho, N Reinmuth, KH Lee, MJ Ahn, A Luft, ... Annals of Oncology 29, x40-x41, 2018 | 115 | 2018 |
| CT074 - Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study … AACR, 2019 | 114* | 2019 |
| Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription–polymerase chain reaction for the detection of anaplastic lymphoma kinase gene … I Demidova, A Barinov, N Savelov, I Gagarin, V Grinevitch, ... Archives of Pathology and Laboratory Medicine 138 (6), 794-802, 2014 | 47 | 2014 |
| Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого КК Лактионов, ЕВ Артамонова, ВВ Бредер, ВА Горбунова, ... Злокачественные опухоли 11 (3S2-1), 36-54, 2021 | 37 | 2021 |
| ПРАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕКАРСТВЕННОМУ ЛЕЧЕНИЮ МЕТАСТАТИЧЕСКИХ ОПУХОЛЕЙ ГОЛОВНОГО МОЗГА ГЛ Кобяков, МИ Куржупов, СВ Медведев, АВ Смолин, АЮ Улитин | 34 | 2017 |
| 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy±atezolizumab in extensive-stage small cell lung cancer SV Liu, L Horn, T Mok, A Mansfield, R De Boer, G Losonczy, S Sugawara, ... Annals of Oncology 31, S1032-S1033, 2020 | 33 | 2020 |
| Brief report: exploratory analysis of maintenance therapy in patients with extensive-stage SCLC treated first line with atezolizumab plus carboplatin and etoposide M Reck, TSK Mok, A Mansfield, R De Boer, G Losonczy, S Sugawara, ... Journal of Thoracic Oncology 17 (9), 1122-1129, 2022 | 21 | 2022 |
| Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D)±tremelimumab (T) versus chemotherapy (CT) in … NA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft, MJ Ahn, ... Journal of Clinical Oncology 37 (15_suppl), 9016-9016, 2019 | 17 | 2019 |
| Практические рекомендации по лекарственному лечению метастатических опухолей головного мозга ДР Насхлеташвили, СМ Банов, АХ Бекяшев, АВ Голанов, ... Злокачественные опухоли, 85-96, 2016 | 17 | 2016 |
| Лечение рецидива глиобластомы: есть ли успехи? ГЛ Кобяков, АВ Смолин, АХ Бекяшев, ОВ Абсалямова, ЕА Кобякова, ... Опухоли головы и шеи, 12-21, 2014 | 17 | 2014 |
| Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide SV Liu, TSK Mok, BY Nabet, AS Mansfield, R De Boer, G Losonczy, ... Lung Cancer 186, 107418, 2023 | 15 | 2023 |
| Первые результаты Российского многоцентрового исследования по эпидемиологии злокачественных глиом AВ Смолин, AХ Бекяшев, AЛ Кобяков, AМ Шарабура, AВ Канищева, ... Современная онкология 16 (2), 50-55, 2015 | 13 | 2015 |
| Химиолучевая терапия мультиформной глиобластомы головного мозга АВ Смолин, АВ Конев, ГЛ Кобяков, СН Николаева, ЮЕ Шаманская Фарматека 7, 41-49, 2011 | 13 | 2011 |
| Возможности антиангиогенной терапии при рецидивах глиом высокой степени злокачественности АВ Смолин, ГЛ Кобяков, АВ Конев, СН Николаева, ЮЕ Шаманская, ... Фарматека, 41-48, 2009 | 13 | 2009 |
Naiyer A. RizviColumbia University在 cumc.columbia.edu 的电子邮件经过验证
